chromobody
vaxin
antimouse
immunofluorohistochemistry
atezolizumab
RAT test
ocrelizumab
immunohistochemical
histocompatibility antigen
immunocompetent
mapatumumab
-lim-
antiantibody
myelosclerosis
cergutuzumab
cytotoxic reaction
antiplasma
polyvalent
abagovomab
tabalumab
ravulizumab
gevokizumab
pidilizumab
affinity
antihistone
brolucizumab
olaratumab
immunocytic
recognition
teprotumumab
specific
tislelizumab
immunosynaptic
teclistamab
preimmunoadsorption
histoimmunochemical
idiospecific
immunoreactively
microlymphocytotoxicity
ipilimumab
immunorepressive
-ab
autocentromere
-les-
antigenic
reagin
iratumumab